SHP Wealth Management
DMRA

SHP Wealth Management’s Damora Therapeutics DMRA Stock Holding History

SHP Wealth Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25
Closed -$575 – 1860
2025
Q4 		$575 Buy
+25
New +$434 ﹤0.01% 1346

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fairmount Funds Management
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VR Adviser
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FCPM III Services
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Remedium Capital Partners
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

SHP Wealth Management's DMRA Position: Q1 2026 in Review

SHP Wealth Management sold out of Damora Therapeutics (DMRA) in Q1 2026, closing a stake of 25 shares — an estimated $575 sold.

SHP Wealth Management first reported a position in DMRA in Q4 2025 and held it in 1 quarter. The position peaked at $575 in Q4 2025. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • SHP Wealth Management reported no remaining Damora Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SHP Wealth Management sold 25 Damora Therapeutics shares in Q1 2026, an estimated $575.
  • SHP Wealth Management first reported a position in Damora Therapeutics in Q4 2025 and held it in 1 quarter.
  • SHP Wealth Management's Damora Therapeutics position peaked at $575 in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.